Repertoire Genesis Inc., (Head office: Ibaraki, Osaka, Japan), has collaborated with Professor MOI MENG LING, Chair, department of developmental medical sciences, school of International Health Graduate School of Medicine, the University of Tokyo, as a leading researcher, had the project to develop a monovalent vaccine against serotype-specific dengue virus that can inhibit antibody-dependent infection enhancement (ADE).

This project was adopted by the Japan Agency for Medical Research and Development (AMED) under its Translational Research Program.
This project is jointly conducted by Professor Shigeyuki Yokoyama, Department of Drug Target Protein Development, Shinshu University School of Medicine, and Repertoire Genesis as member research institutions. Our company is mainly responsible for the prediction and analysis of dengue virus T cell epitopes.

View reference information: Announcement from the University of Tokyo